ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ...

ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ...

Initial inventory stocking was lower than expected due to distributor caution, but it is expected to improve. Cash redemption is higher than expected, with success in prior authorizations. NEPHI is attracting patients due to ease of use, including parents of children with food allergies.

Read More

Did you find this insightful?